TFFP TFF Pharmaceuticals Inc - Ordinary Shares

FDA Catalyst Company
5.09
+0.33  (+7%)
Previous Close 4.76
Open 4.83
52 Week Low 3.6
52 Week High 12.28
Market Cap $129,152,734
Shares 25,373,818
Float 23,840,421
Enterprise Value $75,557,704
Volume 55,425
Av. Daily Volume 128,827
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
B. Riley Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/29/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/05/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/08/2021
Maxim Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/08/2020

Latest News

  1. Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development

    Announced Second CRADA Agreement with USAMRIID and Geneva Foundation to Develop Novel Therapies Using Thin Film Freezing to Combat SARS-CoV-2, Ebola, and Marburg Viruses

    Initiated Phase 2 Trials of Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder With Interim Data for Each Program Expected Later in 2022

    Significant Progress Made in Inhaled Niclosamide Powder Program

    Multiple Abstracts Highlighting Applications of Thin Film Freezing Presented at Respiratory Drug Delivery (RDD) Meeting

    Conference Call and Webcast Scheduled Today, Wednesday, May 11, 2022 at 4:30 PM ET

    FORT WORTH, Texas, May 11, 2022…

    View Full Article
  2. FORT WORTH, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will release its financial results and business update for the first quarter of 2022 on Wednesday, May 11, 2022, after the close of the U.S. financial markets.

    Conference Call and Webcast Information

    The Company will host a conference call on Wednesday, May 11, 2022, at 4:30 PM ET to review the clinical, corporate and financial highlights. A question-and-answer session with investors will follow management's remarks. To participate in the conference…

    View Full Article
  3. Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts

    Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat COVID-19

    FORT WORTH, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced safety and pharmacokinetic (PK) data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed for the treatment of COVID-19.

    "We are very pleased to announce these positive safety and PK data for our Niclosamide Inhalation…

    View Full Article
  4. Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs

    Partnership Activity Surrounding Thin Film Freezing Continues to Expand Reflecting the Technology's Broad Applicability Across Molecule Type and Therapeutic Area

    Appoints Life Sciences Executive, Brandi Roberts, to Board of Directors and Anthony Hickey, Ph.D. as Chief Scientific Officer

    Expands Leadership Team With Senior Appointments in Product Development and Manufacturing, Government and Strategic Initiatives, and Regulatory Affairs

    Conference Call and Webcast Scheduled Today, Thursday, March 24, 2022, at 4:30 PM ET

    FORT WORTH, Texas, March 24, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical…

    View Full Article
View All TFF Pharmaceuticals Inc - Ordinary Shares News